Table 2 Cardiac Echo Measurements.

From: Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats

 

Control

DOCA-salt rats

Serelaxin treated DOCA-salt rats

IVSd (mm)

1.28 ± 0.03

1.53 ± 0.06*

1.33 ± 0.05**

IVSs (mm)

2.00 ± 0.05

2.22 ± 0.07*

2.12 ± 0.09

LVIDd (mm)

7.74 ± 0.17

8.58 ± 0.15*

8.22 ± 0.17

LVIDs (mm)

4.61 ± 0.18

5.42 ± 0.28*

4.79 ± 0.24

IVPWd (mm)

1.28 ± 0.03

1.52 ± 0.06*

1.32 ± 0.05**

LVPWs (mm)

1.99 ± 0.04

2.23 ± 0.07*

2.11 ± 0.09

Heart Rate (BPM)

373.15 ± 6.31

354.36 ± 7.25

405.30 ± 12.04**

LV Vold (ul)

321.65 ± 16.35

403.55 ± 15.46*

367.36 ± 16.90

LV Vols (ul)

99.07 ± 9.60

145.22 ± 16.56*

108.83 ± 12.97

Ejection fraction (%)

69.52 ± 1.58

64.00 ± 3.83

70.79 ± 2.32

  1. All values shown represent the mean ± SEM. N = 6 rats per group. IVSd (Interventricular septal end diastole), IVSs (Interventricular septal end systole), LVIDd (Left ventricular internal diameter end diastole), LVIDs (Left ventricular internal diameter end systole), LVPWd (Left ventricular posterior wall end diastole), LVPWs (Left ventricular posterior wall end systole), LV Vold, (LV diastolic volume), LV Vols (LV systolic volume). Significance: *P < 0.05 vs Control rats; **P < 0.05 vs DOCA-salt rats.
Back to article page